American Society of Clinical Oncology (ASCO)
ASCO is the world's largest oncology professional society; its annual meeting each June is where most practice-changing trials are first presented.
ASCO Annual Meeting (~40,000 attendees), JCO journals, TAPUR basket trial, CancerLinQ, guidelines.
- Annual Meeting
- TAPUR
- Guidelines
Clifford Hudis is a breast oncologist who has run ASCO since 2016.
Prostate cancer trialist who helped bring abiraterone and sipuleucel-T to patients, and led ASCO in 2025-26.
Head and neck cancer leader who established organ-preserving chemoradiation and led ASCO in 2021-22.
At Harlem Hospital in the 1950s she showed methotrexate could shrink breast and skin cancers, tested drugs on patients' own tumour cells, and in 1964 was the only woman among the seven founders of ASCO.
Lori Pierce is a breast radiation oncologist and ASCO past president focused on equity in cancer care.
Lynn Schuchter is a melanoma oncologist who led ASCO in 2023-24.
Community oncologist who led ASCO in 2024-25 with a focus on bringing trials to patients close to home.
Pages like this
not linked directly; found by shared links- InstitutionEuropean Society for Medical Oncology (ESMO)
Shares Cap public prices for new cancer drugs to tiers of the ESMO and ASCO value scales, Micro-learning pushed to community oncologists within 30 days of a practice change, End the abstract-to-paper gap: require full results with any conference presentation, Give negative trials plenary slots at the big cancer conferences.
- CollectionESMO Clinical Practice Guidelines & MCBS
Shares A guideline fast track for repurposed drugs with phase 3 evidence but no manufacturer, ASCO clinical practice guidelines, Living guidelines published as versioned, computable rules, Weak real-world evidence and registries.
- CollectionNCCN Guidelines
Shares Offline decision support for generalists treating common cancers in low-resource settings, A guideline fast track for repurposed drugs with phase 3 evidence but no manufacturer, ASCO clinical practice guidelines, Living guidelines published as versioned, computable rules.
- TermStandard of care
Shares Default-inclusive eligibility: sponsors must justify every exclusion criterion, Living, machine-readable guidelines pushed to the point of care in every country, ASCO clinical practice guidelines, Older and multimorbid patients are excluded and undertreated.
- InstitutionNational Cancer Institute (NIH)
Shares A public equity index for trial sites and sponsors, tied to funding, Every payer covers routine care costs for trial participants, in every country, Lay trial navigators funded per centre, evaluated in a randomised trial, Stop excluding people with a prior cancer, controlled HIV, or treated hepatitis.
- TechnologyAI trial matching & clinical decision support
Shares Just-in-time site activation: open a site in two weeks when a patient appears, HL7 International, Not enough oncologists, nurses, pathologists, physicists, Patients lack understanding, navigation and agency.
- Key paperPrasad: most surrogate endpoints in cancer trials correlate poorly with survival
Shares Power trials to detect a benefit patients would value, not the smallest detectable one, An independent programme that validates surrogate endpoints, setting by setting, Patients lack understanding, navigation and agency, Regulatory divergence between regions.
- CollectionFDA Oncology Approvals (OCE) & Novel Drug Approvals
Shares Older and multimorbid patients are excluded and undertreated, Trials do not represent the people who get cancer, Weak real-world evidence and registries, Regulatory divergence between regions.